Delivery Order SPE2DB20D2104-SPE2DB23FT99X
- Not listed
- This federal contract award, valued at $3,677.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4563217759 units of Ondansetron ODT 4 mg tablets, which are used to treat nausea and vomiting. This is a firm-fixed-price delivery order contract with a completion date of January 4, 2024. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is...
- This federal contract award, valued at $15,158.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,560,679,329 units of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop...
- This federal contract award, valued at $2,321.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,563,063 units of ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The contract has an ultimate completion date of December 12, 2023 and is a firm fixed-price delivery order. It is not designated as a set-aside contract....
- This federal contract award, valued at $10,624.15, was issued to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., by the Defense Logistics Agency (DLA). The contract is a delivery order for the supply of 4,559,022,633 units of 4 mg Ondansetron HCl tablets, a medication used to prevent nausea and vomiting. The contract has a firm fixed price pricing type and an ultimate completion date of November 8, 2022. It is not designated as a set-aside contract....
- This federal contract award, valued at $3,069.22, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,568,062,083 units of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. This is a firm-fixed-price delivery order contract with an ultimate completion date of April 29, 2025. The contract is not set-aside and is open to competition....
- This federal contract award, valued at $5,031.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 4 MG tablets, a medication used to treat nausea and vomiting. The contract is a Delivery Order placed under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at up to $999,999,999.00 and...
- This federal contract award, valued at $16,782.49, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,966,829 units of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 21, 2025. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award, valued at $1,463.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,563,490,062 units of Ondansetron ODT 4 MG Tablet 30S, a medication used to treat nausea and vomiting. The award has an ultimate completion date of January 31, 2024 and is a Firm Fixed Price Delivery Order contract. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a...
- This federal contract award, valued at $11,511.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. The contract is for the delivery of 4565736894 - Ondansetron ODT 4 mg tablets in 30-count packages....
- This federal contract award, valued at $1,084.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,561,805,979 units of the medication Ondansetron ODT 4 mg Tablet. This is a firm-fixed-price delivery order with an ultimate completion date of August 15, 2023. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FT99XDelivery Order
This federal contract award for $2,147.98 was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,561,258,551 units of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. The contract has a firm fixed-price pricing type and an ultimate completion date of June 16, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization that serves as a critical supplier of pharmaceutical products and medical supplies to various government agencies, particularly the Department of Defense and Department of Veterans Affairs healthcare systems. The contract is not designated as a set-aside and was awarded through full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical and medical products to support military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 6/15/23 |